In summary, oral administration of laminarin inhibits acute food intake, improves glucose homeostasis, and chronically exhibits anti-obesity functions, which are associated with GLP-1 secretion. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.